Education
About Us
Working with TipRanks
Follow Us
Olympus (OLYMY)
OTHER OTC:OLYMY
OLYMY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.11 - $19.79
Previous CloseN/A
Volume14.55K
Average Volume (3M)2.60K
Market Cap
$14.76B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)394.79B
Price to Earnings (P/E)19.6
Beta0.72
Next Earnings
Aug 06, 2025EPS EstimateN/A
Last Dividend Ex-Date
Mar 31, 2025Dividend Yield0.57%
Share Statistics
EPS (TTM)0.19
Shares Outstanding1,139,116,300
10 Day Avg. Volume0
30 Day Avg. Volume2,600
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Olympus News
PremiumCompany Announcements
Olympus Corp. Adr’s Earnings Call Highlights Growth and Challenges
PremiumCompany Announcements
Olympus Corp. Reports Strong Revenue Growth in 2025
PremiumPre-Earnings
Is OLYMY a Buy, Before Earnings?
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
OLYMY FAQ
What was Olympus’s price range in the past 12 months?
Olympus lowest stock price was $11.11 and its highest was $19.79 in the past 12 months.
What is Olympus’s market cap?
Olympus’s market cap is $14.76B.
When is Olympus’s upcoming earnings report date?
Olympus’s upcoming earnings report date is Aug 06, 2025 which is in 47 days.
How were Olympus’s earnings last quarter?
Olympus released its earnings results on May 13, 2025. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.162 by $0.088.
Is Olympus overvalued?
According to Wall Street analysts Olympus’s price is currently Overvalued.
Does Olympus pay dividends?
Olympus pays a Notavailable dividend of $0.094 which represents an annual dividend yield of 0.57%. See more information on Olympus dividends here
What is Olympus’s EPS estimate?
Olympus’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Olympus have?
Olympus has 1,139,116,300 shares outstanding.
What happened to Olympus’s price movement after its last earnings report?
Olympus reported an EPS of $0.25 in its last earnings report, beating expectations of $0.162. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Olympus?
Currently, no hedge funds are holding shares in OLYMY
Olympus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.44%
12-Months-Change
Fundamentals
Return on Equity
15.47%
Trailing 12-Months
Asset Growth
-5.48%
Trailing 12-Months
Company Description
Olympus
Olympus Corp. is engaged in the manufacture and sale of precision machineries and instruments. It operates through the following segments: Medical Systems, Life Sciences and Industrial, Imaging Systems, Information and Communications, and Others. The Medical Systems segment covers endoscopes, and endoscopic surgery and therapy. The Life Sciences and Industrial segment manufactures and sells biological and industrial microscopes, industrial endoscopes, non-destructive testing equipment, and printers. The Imaging Systems segment deals with digital cameras and recording devices. The Information and Communication segment sells mobile terminals such as mobile phones. The Others segment includes biomaterial manufacturing and sales, and system development. The company was founded by Takeshi Yamashita on October 12, 1919 and is headquartered in Tokyo, Japan.
OLYMY Company Deck
OLYMY Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong sales growth in North America and record revenue achievement, alongside a dividend increase and new product launches. However, challenges in China, potential impacts from U.S. tariffs, and increased R&D expenses present notable concerns. The appointment of a new CEO is seen as a positive step towards addressing these challenges.Read More>